Evidence map›Paper›PMID 24676270›Full record

ArticlePloS one2014

Endogenous IL-22 plays a dual role in arthritis: regulation of established arthritis via IFN-γ responses.

Shivali Justa, Xiaoqun Zhou, Sujata Sarkar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 51 citations in OpenAlex.

  1. IL-22 synergizes with IL-17 to promote mucosal inflammation and bone loss.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Interleukin-22 Influences the Th1/Th17 Axis.Frontiers in immunology · 2021
    Review
  8. Article
  9. Review
  10. IL-22 increases the production of sFRP3 by FLS in inflammatory joint diseases.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Article
  11. Review
  12. Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.Cold Spring Harbor perspectives in biology · 2019
    Review
  13. IL-22 promotes allergic airway inflammation in epicutaneously sensitized mice.The Journal of allergy and clinical immunology · 2019
    Article
  14. Interleukin 22 Expands Transit-Amplifying Cells While Depleting Lgr5Cellular and molecular gastroenterology and hepatology · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shivali JustaSection of Rheumatology, Department of Medicine, and the Arizona Arthritis Center, University of Arizona, Tucson, Arizona, United States of America.
Xiaoqun ZhouSection of Rheumatology, Department of Medicine, and the Arizona Arthritis Center, University of Arizona, Tucson, Arizona, United States of America.
Sujata SarkarSection of Rheumatology, Department of Medicine, and the Arizona Arthritis Center, University of Arizona, Tucson, Arizona, United States of America.
University of Arizona · US

Funding

Mentored Clinical Scientist Research Career Development AwardK08AR054323 · NIAMS · UNIVERSITY OF ARIZONA · PI SARKAR, SUJATA · 2009 to 2013
$566k
NIAMS NIH HHS AR054323NIAMS NIH HHS K08 AR054323
6 · The paper itself

Abstract

objectiveIL-22 is elevated in patients with inflammatory arthritis and correlates with disease activity. IL-22 deficient mice have reduced incidence of arthritis. Recombinant IL-22 restrains progression of arthritis via increase in IL-10 responses when administered prior to onset of arthritis. These findings imply a possible dual role of IL-22 in inflammatory arthritis depending on the phase of arthritis. Experiments outlined here were designed to elucidate the contribution of endogenous IL-22 before and after the onset of arthritis.

methodsCollagen induced arthritis (CIA) was induced in DBA1 or IFN-γ deficient mice following immunization with collagen and complete Freund's adjuvant. Anti-IL-22 antibody or isotype control were administered prior to or after onset of arthritis and disease progression assessed by clinical scoring and histopathology. IL-22, IL-17 and IFN-γ responses were measured by ELISA and flowcytometry. Anti-collagen antibody responses were analyzed by ELISA. Expression of IL-22R1 in CD4+ cells was elucidated by flowcytometry and real time PCR.

resultsCollagen specific IL-22 responses were expanded during arthritis and IL-22 producing cells were discrete from IL-17 or IFN-γ producing cells. Neutralization of IL-22 after onset of arthritis resulted in significant increase in Th1 responses and significantly reduced severity of arthritis. CD4+ cells from arthritic mice showed increased surface expression of IL-22R1. In vitro, CD4+T cells cultured with antigen presenting cells in the presence or absence of IL-22 suppressed or induced IFN-γ, respectively. The protective effect of anti-IL-22 was reversed in IFN-γ deficient mice. Moreover, administration of anti-IL-22 prior to onset of arthritis augmented arthritis severity.

conclusionWe show for the first time that IL-22 plays a dual role: protective prior to the onset of arthritis and pathogenic after onset of arthritis. The pathogenic effect of IL-22 is dependent on suppression of IFN-γ responses. IL-17 responses remained unchanged with the administration of anti-IL22 antibody. IL-22R1 is upregulated on CD4+T cells during arthritis and regulates IFN-γ in T cells.

Indexed as

AnimalsAntibodies, NeutralizingArthritis, ExperimentalCollagenFemaleFreund's AdjuvantGene Expression RegulationInterferon-gammaInterleukin-17Interleukin-22InterleukinsMaleMiceMice, Inbred DBAMice, KnockoutReceptors, InterleukinAntibodies, NeutralizingCollagenFreund's AdjuvantInterferon-gammaInterleukin-17Interleukin-22interleukin-22 receptorInterleukinsReceptors, Interleukin

Identifiers

PMID24676270
PMCPMC3968131
OpenAlexW2053285708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.